AstraZeneca Strikes AI Drug Discovery Deal Worth Up to $1.5 Billion
AstraZeneca said it will work with Insitro to use AI to explore treatments for cardiometabolic diseases. The deal includes $40 million upfront, with additional payments bringing its value to as much as $1.5 billion.
By Adria CalatayudAstraZeneca said it is teaming up with startup Insitro to deploy artificial intelligence to explore new treatments for cardiometabolic diseases in a deal valued at as much as $1.5 billion.The U.K. drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1…